Efavirenz liquid formulation in human immunodeficiency virus-infected children

Stuart E. Starr, Courtney V. Fletcher, Stephen A. Spector, Richard C. Brundage, Florence H. Yong, Steven D. Douglas, Patrizia M. Flynn, Mark W. Kline

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background. This study determined the safety, pharmacokinetics, antiviral activity and immunologic effects of efavirenz liquid formulation, nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected children, 3 to 9 years of age. Methods. Plasma HIV-1 RNA and lymphocyte subsets were measured at various intervals after initiation of therapy. Pharmacokinetic studies were performed at Week 2, and doses of efavirenz and nelfinavir were adjusted if area under the curve values fell outside specified target ranges. Results. This combination of antiretrovirals was well-tolerated. Pharmacokinetic values were similar to those observed in a previous study of older children who received efavirenz capsules in combination with nelfinavir and NRTIs. After 48 weeks of therapy 63% of subjects had plasma HIV RNA levels of <400 copies/ml, and 58% had <50 copies/ml in an intent-to-treat analysis. CD4 cell count and percentage rose significantly over this time, whereas the number of activated CD8 cells declined. Conclusions. Combination therapy with efavirenz liquid formulation, nelfinavir and NRTIs is an attractive treatment option for HIV infected children >3 years of age who are unable to take efavirenz capsules.

Original languageEnglish (US)
Pages (from-to)659-663
Number of pages5
JournalPediatric Infectious Disease Journal
Volume21
Issue number7
DOIs
StatePublished - Jul 23 2002

Fingerprint

efavirenz
Nelfinavir
HIV
Reverse Transcriptase Inhibitors
Pharmacokinetics
Nucleosides
Capsules
RNA
Lymphocyte Subsets
Area Under Curve
Antiviral Agents
HIV-1
Safety
Therapeutics

Keywords

  • Antiretroviral therapy
  • Efavirenz
  • Pediatric human immunodeficiency virus infection
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Starr, S. E., Fletcher, C. V., Spector, S. A., Brundage, R. C., Yong, F. H., Douglas, S. D., ... Kline, M. W. (2002). Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal, 21(7), 659-663. https://doi.org/10.1097/00006454-200207000-00011

Efavirenz liquid formulation in human immunodeficiency virus-infected children. / Starr, Stuart E.; Fletcher, Courtney V.; Spector, Stephen A.; Brundage, Richard C.; Yong, Florence H.; Douglas, Steven D.; Flynn, Patrizia M.; Kline, Mark W.

In: Pediatric Infectious Disease Journal, Vol. 21, No. 7, 23.07.2002, p. 659-663.

Research output: Contribution to journalArticle

Starr, SE, Fletcher, CV, Spector, SA, Brundage, RC, Yong, FH, Douglas, SD, Flynn, PM & Kline, MW 2002, 'Efavirenz liquid formulation in human immunodeficiency virus-infected children', Pediatric Infectious Disease Journal, vol. 21, no. 7, pp. 659-663. https://doi.org/10.1097/00006454-200207000-00011
Starr, Stuart E. ; Fletcher, Courtney V. ; Spector, Stephen A. ; Brundage, Richard C. ; Yong, Florence H. ; Douglas, Steven D. ; Flynn, Patrizia M. ; Kline, Mark W. / Efavirenz liquid formulation in human immunodeficiency virus-infected children. In: Pediatric Infectious Disease Journal. 2002 ; Vol. 21, No. 7. pp. 659-663.
@article{0eb5f89866a74501871910af2d6b6404,
title = "Efavirenz liquid formulation in human immunodeficiency virus-infected children",
abstract = "Background. This study determined the safety, pharmacokinetics, antiviral activity and immunologic effects of efavirenz liquid formulation, nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected children, 3 to 9 years of age. Methods. Plasma HIV-1 RNA and lymphocyte subsets were measured at various intervals after initiation of therapy. Pharmacokinetic studies were performed at Week 2, and doses of efavirenz and nelfinavir were adjusted if area under the curve values fell outside specified target ranges. Results. This combination of antiretrovirals was well-tolerated. Pharmacokinetic values were similar to those observed in a previous study of older children who received efavirenz capsules in combination with nelfinavir and NRTIs. After 48 weeks of therapy 63{\%} of subjects had plasma HIV RNA levels of <400 copies/ml, and 58{\%} had <50 copies/ml in an intent-to-treat analysis. CD4 cell count and percentage rose significantly over this time, whereas the number of activated CD8 cells declined. Conclusions. Combination therapy with efavirenz liquid formulation, nelfinavir and NRTIs is an attractive treatment option for HIV infected children >3 years of age who are unable to take efavirenz capsules.",
keywords = "Antiretroviral therapy, Efavirenz, Pediatric human immunodeficiency virus infection, Pharmacokinetics",
author = "Starr, {Stuart E.} and Fletcher, {Courtney V.} and Spector, {Stephen A.} and Brundage, {Richard C.} and Yong, {Florence H.} and Douglas, {Steven D.} and Flynn, {Patrizia M.} and Kline, {Mark W.}",
year = "2002",
month = "7",
day = "23",
doi = "10.1097/00006454-200207000-00011",
language = "English (US)",
volume = "21",
pages = "659--663",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Efavirenz liquid formulation in human immunodeficiency virus-infected children

AU - Starr, Stuart E.

AU - Fletcher, Courtney V.

AU - Spector, Stephen A.

AU - Brundage, Richard C.

AU - Yong, Florence H.

AU - Douglas, Steven D.

AU - Flynn, Patrizia M.

AU - Kline, Mark W.

PY - 2002/7/23

Y1 - 2002/7/23

N2 - Background. This study determined the safety, pharmacokinetics, antiviral activity and immunologic effects of efavirenz liquid formulation, nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected children, 3 to 9 years of age. Methods. Plasma HIV-1 RNA and lymphocyte subsets were measured at various intervals after initiation of therapy. Pharmacokinetic studies were performed at Week 2, and doses of efavirenz and nelfinavir were adjusted if area under the curve values fell outside specified target ranges. Results. This combination of antiretrovirals was well-tolerated. Pharmacokinetic values were similar to those observed in a previous study of older children who received efavirenz capsules in combination with nelfinavir and NRTIs. After 48 weeks of therapy 63% of subjects had plasma HIV RNA levels of <400 copies/ml, and 58% had <50 copies/ml in an intent-to-treat analysis. CD4 cell count and percentage rose significantly over this time, whereas the number of activated CD8 cells declined. Conclusions. Combination therapy with efavirenz liquid formulation, nelfinavir and NRTIs is an attractive treatment option for HIV infected children >3 years of age who are unable to take efavirenz capsules.

AB - Background. This study determined the safety, pharmacokinetics, antiviral activity and immunologic effects of efavirenz liquid formulation, nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected children, 3 to 9 years of age. Methods. Plasma HIV-1 RNA and lymphocyte subsets were measured at various intervals after initiation of therapy. Pharmacokinetic studies were performed at Week 2, and doses of efavirenz and nelfinavir were adjusted if area under the curve values fell outside specified target ranges. Results. This combination of antiretrovirals was well-tolerated. Pharmacokinetic values were similar to those observed in a previous study of older children who received efavirenz capsules in combination with nelfinavir and NRTIs. After 48 weeks of therapy 63% of subjects had plasma HIV RNA levels of <400 copies/ml, and 58% had <50 copies/ml in an intent-to-treat analysis. CD4 cell count and percentage rose significantly over this time, whereas the number of activated CD8 cells declined. Conclusions. Combination therapy with efavirenz liquid formulation, nelfinavir and NRTIs is an attractive treatment option for HIV infected children >3 years of age who are unable to take efavirenz capsules.

KW - Antiretroviral therapy

KW - Efavirenz

KW - Pediatric human immunodeficiency virus infection

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0036020187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036020187&partnerID=8YFLogxK

U2 - 10.1097/00006454-200207000-00011

DO - 10.1097/00006454-200207000-00011

M3 - Article

C2 - 12237599

AN - SCOPUS:0036020187

VL - 21

SP - 659

EP - 663

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 7

ER -